Last reviewed · How we verify
NCT05091008
Treatment of Chronic Hepatitis C Infection by Ledipasvir/Sofosbuvir in Naïve Children
Phase 2 trial testing Ledipasvir-Sofosbuvir 90 Mg-400 Mg Oral Tablet in Hepatitis C, Chronic in 50 participants. Completed in 10 March 2020.
30 August 2019
Quick facts
| Lead sponsor | Mansoura University Children Hospital |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 50 |
| Start date | 1 March 2018 |
| Primary completion | 30 August 2019 |
| Estimated completion | 10 March 2020 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- Ledipasvir-Sofosbuvir 90 Mg-400 Mg Oral Tablet — full drug profile →
Conditions studied
- Hepatitis C, Chronic — all drugs for Hepatitis C, Chronic →
Sponsor
Mansoura University Children Hospital
Who can join
Adults 12 to 18, any sex, with Hepatitis C, Chronic. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Chronic hepatitis C virus (HCV) infection represents a crucial health problem in children that greatly influence their quality of life. Many efforts have been directed toward the investment of effective drugs with high safety profiles and with oral administration for better compliance. The development of a new direct-acting antiviral (DAA) made it possible to achieve these goals.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05091008
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hepatitis C, Chronic
Currently open trials in the same condition.
- NCT04014179 — Enhancing Hepatitis C Testing and Treatment Among People Who Inject Drugs Attending Needle and Syringe Programs · NA · active not recruiting
- NCT04943588 — Treating Hepatitis C in Pakistan. Strategies to Avoid Resistance to Antiviral Drugs · recruiting
- NCT03520660 — People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents · Phase 4 · active not recruiting
- NCT03200379 — Nation-wide Hepatitis C Virus (HCV) Registry in Taiwan · recruiting
Other Mansoura University Children Hospital trials
Trials by the same sponsor.
- NCT05589909 — Performance of Interleukin-27 Cord Blood Level as A Biomarker Predicating Early Onset Neonatal Sepsis · unknown
- NCT04474327 — Role of Montelukast in Modulation of Response to Sepsis in Preterm Infants · Phase 1 · completed
- NCT03731611 — Impact of Umbilical Cord Milking in Preterm Neonates With Placental Insufficiency · NA · completed
- NCT05596656 — IgE-mediated Allergies Among Type 1 Diabetes Mellitus Children, Single Centre Observational Study · completed
- NCT04958616 — House Dust Mites Sensitization and Level of Asthma Control and Severity in Children · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05091008 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Mansoura University Children Hospital
- Last refreshed: 25 October 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05091008.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing